VIGL

Vigil Neuroscience, Inc.

3.73 USD
+0.01 (+0.27%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Vigil Neuroscience, Inc. stock is down -10.98% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 July’s closed higher than June. 100% of analysts rate it a buy.

About Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc. engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) The company also develops a small molecule TREM2 agonist suitable for oral delivery.

  • Wedbush
    Thu Jul 11, 10:13
    buy
    confirm
  • Wedbush
    Fri Jun 28, 09:03
    buy
    confirm
  • HC Wainwright & Co.
    Fri Jun 28, 07:28
    buy
    confirm